FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016506024> ?p ?o ?g. }

• W2016506024 endingPage "141" @default.
• W2016506024 startingPage "134" @default.
• W2016506024 abstract "To date, blockade of growth factor receptors is the mainstay of targeted therapy in metastatic breast cancer (mBC). Monoclonal antibodies such as trastuzumab and bevacizumab represent the first generation of molecular-based therapies. Both the HER2 inhibitors and the vascular endothelial growth factor (VEGF) antagonists have shown synergism with a broad spectrum of established cytotoxins, thus being approved for first-line treatment of mBC in combination with taxanes. As a next step, tyrosine kinase inhibitors (TKIs) have been integrated into daily routine as an alternative approach for targeting HER2: The dual HER1/2 inhibitor lapatinib demonstrated activity in trastuzumab-pretreated mBC patients in combination with capecitabine. Furthermore, chemotherapy-free regimens (trastuzumab or lapatinib plus aromatase inhibitors) have been identified as additional options for hormone receptor (HR)- and HER2-positive patients. Recently published data indicate that a combination of two biologicals such as lapatinib and trastuzumab can be effective as a treatment beyond trastuzumab related progression. Multitarget TKIs have the potential to inhibit several signaling pathways involved in breast cancer-related angiogenesis. Until now, they have failed to show a clear benefit in mBC. On the other hand, poly(ADP-ribose) polymerase (PARP) inhibition, mediated by a new class of small molecules, is an interesting area of investigation. Future directions of research in HER2-positive breast cancer focus on the evaluation of novel antibodies (pertuzumab, T-DM1), and irreversible TKIs (neratinib, BIBW 2992) and inhibitors of HER2-related downstream signaling (mTOR, TORC 1/2, PI3K/Akt) and of receptor cross-talk (IGFR)." @default.
• W2016506024 created "2016-06-24" @default.
• W2016506024 creator A5023548284 @default.
• W2016506024 creator A5050289740 @default.
• W2016506024 date "2010-01-01" @default.
• W2016506024 modified "2023-09-24" @default.
• W2016506024 title "The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer" @default.
• W2016506024 cites W1974114904 @default.
• W2016506024 cites W1984007340 @default.
• W2016506024 cites W1992261227 @default.
• W2016506024 cites W2012784647 @default.
• W2016506024 cites W2020372547 @default.
• W2016506024 cites W2046705215 @default.
• W2016506024 cites W2049208654 @default.
• W2016506024 cites W2053317107 @default.
• W2016506024 cites W2057706543 @default.
• W2016506024 cites W2071318151 @default.
• W2016506024 cites W2097698108 @default.
• W2016506024 cites W2101299592 @default.
• W2016506024 cites W2101824720 @default.
• W2016506024 cites W2103563357 @default.
• W2016506024 cites W2103979740 @default.
• W2016506024 cites W2105196235 @default.
• W2016506024 cites W2108182027 @default.
• W2016506024 cites W2110444464 @default.
• W2016506024 cites W2114159573 @default.
• W2016506024 cites W2114195503 @default.
• W2016506024 cites W2118605519 @default.
• W2016506024 cites W2126275851 @default.
• W2016506024 cites W2126575569 @default.
• W2016506024 cites W2131705241 @default.
• W2016506024 cites W2133105825 @default.
• W2016506024 cites W2136704455 @default.
• W2016506024 cites W2137086207 @default.
• W2016506024 cites W2140055441 @default.
• W2016506024 cites W2146062596 @default.
• W2016506024 cites W2149773268 @default.
• W2016506024 cites W2149952977 @default.
• W2016506024 cites W2149997750 @default.
• W2016506024 cites W2153982924 @default.
• W2016506024 cites W2157285286 @default.
• W2016506024 cites W2163003060 @default.
• W2016506024 cites W2165003903 @default.
• W2016506024 cites W2168814163 @default.
• W2016506024 cites W2171972386 @default.
• W2016506024 cites W2207221522 @default.
• W2016506024 cites W2244529370 @default.
• W2016506024 cites W2247075085 @default.
• W2016506024 cites W2318605753 @default.
• W2016506024 cites W2460467689 @default.
• W2016506024 cites W3081058368 @default.
• W2016506024 doi "https://doi.org/10.1159/000314996" @default.
• W2016506024 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2931051" @default.
• W2016506024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20847826" @default.
• W2016506024 hasPublicationYear "2010" @default.
• W2016506024 type Work @default.
• W2016506024 sameAs 2016506024 @default.
• W2016506024 citedByCount "9" @default.
• W2016506024 countsByYear W20165060242012 @default.
• W2016506024 countsByYear W20165060242014 @default.
• W2016506024 countsByYear W20165060242016 @default.
• W2016506024 countsByYear W20165060242019 @default.
• W2016506024 countsByYear W20165060242022 @default.
• W2016506024 crossrefType "journal-article" @default.
• W2016506024 hasAuthorship W2016506024A5023548284 @default.
• W2016506024 hasAuthorship W2016506024A5050289740 @default.
• W2016506024 hasBestOaLocation W20165060241 @default.
• W2016506024 hasConcept C121608353 @default.
• W2016506024 hasConcept C126322002 @default.
• W2016506024 hasConcept C143998085 @default.
• W2016506024 hasConcept C2775930923 @default.
• W2016506024 hasConcept C2776694085 @default.
• W2016506024 hasConcept C2777329042 @default.
• W2016506024 hasConcept C2777802072 @default.
• W2016506024 hasConcept C2777909004 @default.
• W2016506024 hasConcept C2779413316 @default.
• W2016506024 hasConcept C2779786085 @default.
• W2016506024 hasConcept C2781164504 @default.
• W2016506024 hasConcept C2781230642 @default.
• W2016506024 hasConcept C502942594 @default.
• W2016506024 hasConcept C526805850 @default.
• W2016506024 hasConcept C530470458 @default.
• W2016506024 hasConcept C71924100 @default.
• W2016506024 hasConcept C98274493 @default.
• W2016506024 hasConceptScore W2016506024C121608353 @default.
• W2016506024 hasConceptScore W2016506024C126322002 @default.
• W2016506024 hasConceptScore W2016506024C143998085 @default.
• W2016506024 hasConceptScore W2016506024C2775930923 @default.
• W2016506024 hasConceptScore W2016506024C2776694085 @default.
• W2016506024 hasConceptScore W2016506024C2777329042 @default.
• W2016506024 hasConceptScore W2016506024C2777802072 @default.
• W2016506024 hasConceptScore W2016506024C2777909004 @default.
• W2016506024 hasConceptScore W2016506024C2779413316 @default.
• W2016506024 hasConceptScore W2016506024C2779786085 @default.
• W2016506024 hasConceptScore W2016506024C2781164504 @default.
• W2016506024 hasConceptScore W2016506024C2781230642 @default.
• W2016506024 hasConceptScore W2016506024C502942594 @default.
• W2016506024 hasConceptScore W2016506024C526805850 @default.

• next